Introduction
Antibody-drug conjugates (ADCs) are a class of drugs characterized by antibody scaffolds covalently modified with
variable numbers of small molecule payloads. These drugs are mixed entities that combine biological and small
molecule features. It combines the high targeting of monoclonal antibodies and the high efficiency of small molecule
drugs in removing cancer cells, and can synergistically play the respective advantages of antibody drugs and
chemical drugs. Antibodies are used to specifically target small molecules to target cell types. However, there are
many unpredictable problems in the process of antibody drug conjugation, such as some of the antibodies and small
molecules may not be successfully conjugated; there are multiple binding sites in the antibody; different Drug
antibody ratio (DAR) may lead to change of hydrophobicity of the final ADC, etc. The existence of these problems may
have a relatively large impact on the efficacy and safety of ADCs. At the same time, because the production process
of ADCs is more complicated, the quality of ADCs needs to be strictly monitored. Therefore, the sequencing analysis
of antibody-drug conjugates is of great significance.
Fig.
1. Schematic representation of ADC, showing the main components of an ADC and its cell cytotoxicity mechanism.
(Nejadmoghaddam M R, et al., 2019)
Our Services
Creative Proteomics has developed the advanced mass spectrometry sequencing platform for ADC, with a
high-resolution mass spectrometry analysis instruments. Combined with a professional bioinformatics analysis team,
we can quickly and accurately provide you with professional and systematic ADC sequencing services. Our experienced
scientists use the antibody sequencing platform developed by the company, using DASS (Database Assisted Shotgun
Sequencing) technology, combined with the advantages of existing technology to analyze antibodies. It is an antibody
sequencing platform based on mass spectrometry technology that this technology is also applicable to other subtypes
and different forms of antibodies, such as: IgM, fluorescent conjugated antibodies, immobilized antibodies,
antibodies of different species, etc.
At Creative Proteomics, the antibody-drug conjugate (ADC) sequencing service can provide
professional monoclonal antibody sequencing services according to customer requirements, ensuring 100% accurate
sequencing for all species, isotype antibodies or allotype antibodies.
Applications
- Identification of Antibody Conjugates
The traditional coupling method covalently connects cytotoxic drugs
to lysine residues on antibodies or cysteine residues generated by the reduction of interchain disulfide bonds,
and the obtained ADCs have a drug-to-antibody ratio , DAR) and coupling sites are highly variable, leading to
greater heterogeneity. The conjugated antibody sequencing service can effectively identify the types of antibody
conjugated drugs.
- Detection of OCFS-Conjugated Antibody Production
Deletion of the OCFS cell wall can add non-native factors
to the system to manipulate transcription, translation and folding for precise regulation of protein expression
processes. Conjugated antibody sequencing services can detect changes in the production of conjugated
antibodies.
Creative Proteomics has accumulated extensive experience in the discovery and sequencing of
therapeutic antibodies and proteins. We provide professional antibody-drug conjugate (ADC) sequencing services for
global customers. Our team has successfully sequenced thousands of antibodies to help researchers decode their
antibodies in a fraction of the time. Therefore, please contact us if you
are interested in our antibody sequencing services.
References
- Ponziani S, Vittorio G D, Pitari G, et al. (2020) Antibody-Drug Conjugates: The New Frontier of
Chemotherapy. Int J Mol Sci. 21(15):5510.
- Nejadmoghaddam M R, Arash M T, Ghahremanzadeh R, et al. (2019) Antibody-Drug Conjugates: Possibilities
and Challenges. Avicenna J Med Biotechnol. 1(1):3-23.
